BioCryst Raises $350M to Support Orladeyo’s Global Launch

BioCryst Raises $350M to Support Orladeyo’s Global Launch

313206

BioCryst Raises $350M to Support Orladeyo’s Global Launch

BioCryst Pharmaceuticals has received funds worth $350 million that will be used in part to support the global launch of Orladeyo (berotralstat), an oral therapy to prevent hereditary angioedema (HAE) swelling attacks. The money came through various transactions with Royalty Pharma, a global buyer of pharmaceutical royalties, and Omers Capital Markets, a defined benefit pension plans company in Canada. “Almost a year into its launch, BioCryst has established Orladeyo as a leading HAE prophylactic [preventive] therapy,”…

You must be logged in to read/download the full post.